Zepbound (tirzepatide) / Eli Lilly - LARVOL DELTA

Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration. (PubMed, J Obes) - P3 | "Introduction: Tirzepatide, a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide 1 (GLP-1) analogue, is a novel medication with comparable pharmacological characteristics and has demonstrated promising weight reduction outcomes in its antidiabetic trials following the approval of liraglutide and semaglutide for long-term weight control. However, the lean mass reduction and tolerability require further investigation. Trial Registration: ClinicalTrials.gov identifier: NCT04255433."

Clinical • Journal • Retrospective data • Genetic Disorders • Obesity • Type 2 Diabetes Mellitus

HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis. (PubMed, Diabetes Obes Metab) - "The tirzepatide-induced HbA1c reductions from baseline, compared with placebo or semaglutide, were mediated through both WL-D and WL-IND effects. Estimated contributions of WL to the difference in glycaemic efficacy varied and were highest when tirzepatide was compared with semaglutide and less pronounced when compared with placebo. These results help to understand that other factors beyond weight reduction contribute to HbA1c reduction with tirzepatide."

Journal • Diabetes • Metabolic Disorders • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "While gastrointestinal side effects were common, they were generally mild to moderate and did not increase serious adverse events. These findings support tirzepatide as an effective weight management therapy, though strategies to mitigate gastrointestinal symptoms may improve adherence."

Clinical • Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects. (PubMed, Obes Facts) - "The EASO framework aims to optimize pharmacological treatment for obesity through an individualized, evidence-based approach. By integrating clinical efficacy, safety outcomes, and patient-specific factors, these guidelines will support healthcare professionals in improving obesity management and its related comorbidities."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

Tirzepatide Use in People With Obesity and Type 1 Diabetes (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Dasman Diabetes Institute

New P4 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Triple Agonism Based Therapies for Obesity. (PubMed, Curr Cardiovasc Risk Rep) - "Other unimolecular triple agonists and combination regimens involving tirzepatide with additional mono agonists are also in development. Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023. (PubMed, Front Med (Lausanne)) - "The largest share of the market growth in 2023 was driven by these medications. The significant increase in AOM utilization and spending highlights the growing burden of obesity on Medicaid, emphasizing the need for policy measures to manage rising costs and ensure equitable access to treatment."

Journal • Reimbursement • US reimbursement • Genetic Disorders • Infectious Disease • Novel Coronavirus Disease • Obesity

From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics. (PubMed, Neurotherapeutics) - "GLP-1 receptor agonists (GLP-1RAs), initially approved for diabetes and obesity, are now under investigation for neuroprotective effects in a range of neurological disorders...Newer agents, such as NLY01 and tirzepatide, are under development to enhance central nervous system penetration and efficacy. Although GLP-1RAs are generally safe in metabolic conditions, their use in neurological diseases requires careful monitoring and patient selection. Future directions include developing reliable biomarkers, implementing precision medicine strategies, and exploring the use of combination therapies to maximize therapeutic potential."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Multiple Sclerosis • Obesity • Parkinson's Disease

TiLi-BONE: Tirzepatide vs Liraglutide in Bone (clinicaltrials.gov) - P=N/A | N=72 | Recruiting | Sponsor: National and Kapodistrian University of Athens

New trial • Genetic Disorders • Obesity

Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions. (PubMed, Nutrients) - "Therapeutic strategies targeting weight loss may alter disease trajectories, improve outcomes, and reduce cancer risk. Further research is needed to define optimal intervention strategies and to identify and validate biomarkers for personalized risk assessment and prevention."

Journal • Review • Dyslipidemia • Gastroenterology • Genetic Disorders • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Solid Tumor

TRANSFORM: Transplant Readiness Achieved through Novel Solutions for Obesity Reduction and Management (WTC 2025) - "Early analysis of IBT for pre-transplant weight loss shows promising results in % weight loss and BMI reduction. Adverse effects were similar in type and frequency as those reported in the general population. Longer follow-up studies are needed to assess further effectiveness and safety."

Constipation • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity • Transplantation

Impact of Glucagon Like Peptide-1 (GLP-1) Analogue Medications on Liver Transplant Risk Factors (WTC 2025) - "In our cohort, the use of GLP-1 analogues was not associated with cancer in patients who undergo liver transplantation. We were limited by single center and smaller number of patients. Further large scale, multicenter studies are needed to confirm the safety of these medications."

Clinical • Biliary Cancer • Cholangiocarcinoma • Chronic Kidney Disease • Diabetes • Follicular Lymphoma • Genetic Disorders • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Lymphoma • Melanoma • Metabolic Disorders • Obesity • Prostate Cancer • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Transplantation

Decreased Rate of Rejections Post Liver Transplant in Patients on a Glucagon-Like Peptide 1 (GLP-1) Analogue (WTC 2025) - "In our cohort, the use of semaglutide and tirzepatide was associated with a decreased incidence of liver transplant rejections in patients with BMI > 30. We were limited by single center and smaller number of patients. Further large scale, multicenter studies are needed to confirm the efficacy of these medications, possibly suggesting a more significant role post liver transplant."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Renal Disease • Transplant Rejection • Transplantation

Tirzepatide Safely Improves Obesity and Glycemic Control in Diabetic Kidney Transplant Recipients (WTC 2025) - "Data were compared with 13 cases treated with liraglutide (LRG)... TRZ was effective for weight loss and improving glycemic control in obese kidney transplant recipients with type 2 diabetes."

Clinical • Diabetes • Diabetic Nephropathy • Genetic Disorders • Metabolic Disorders • Obesity • Transplantation • Type 2 Diabetes Mellitus

Glucagon-Like Peptide-1 Receptor Analogs for Weight Loss in Advanced Chronic Kidney Disease Patients Waiting for a Kidney Transplant - A Nephrologist-Driven Approach (WTC 2025) - "66% were on insulin, one on Dapagliflozin, and one was not on any antihyperglycemic agents. The following cases demonstrate a proof of concept for the safe and effective use of the GLP1 RA for weight loss in obese, diabetic, and advanced CKD patients who cannot undergo renal transplantation due to obesity. Improved insurance coverage can help expand GLP1RA usage to non-diabetics with obesity awaiting kidney transplants."

Clinical • Metastases • Chronic Kidney Disease • Genetic Disorders • Nephrology • Obesity • Pancreatic Cancer • Pancreatitis • Renal Disease • Solid Tumor • Transplantation

Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real World Experience from a Single Center Study (WTC 2025) - "In conclusion, in this real-world experience, tirzepatide use is tolerable and effective in KTR with diabetes and obesity. However, weight loss and CNI dosing requirements should be closely monitored to ensure CNI trough concentrations remain therapeutic."

Clinical • Real-world • Real-world evidence • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Transplantation

TZP-T1D: Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Royal North Shore Hospital | Trial completion date: Apr 2027 ➔ Dec 2028 | Trial primary completion date: Oct 2026 ➔ Dec 2028

Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies. (PubMed, Panminerva Med) - "Notably, the combinations of GLP-1 RA, GIP and glucagon RA (retatrutide) have shown WL efficacy closing on to that observed in bariatric surgery. While entero-pancreatic hormone-based therapies have been the centre of attention for obesity pharmacotherapies, non- entero-pancreatic hormone treatments also hold promise. In this review, we present the future pharmacotherapies for weight management in people with obesity, focusing on entero-pancreatic hormone-based molecules."

Journal • Genetic Disorders • Obesity

The Drug Update: Recent drug approvals, summer 2025 edition. (PubMed, Nurse Pract) - "This article highlights the following new medications: donanemab-azbt (Kisunla), nalmefene injection (Zurnai), epinephrine nasal spray (neffy), palopegteriparatide (Yorvipath), xanomeline and trospium chloride (Cobenfy), and sulopenem etzadroxil/probenecid (Orlynvah). Additionally, this article highlights the recent approval of obstructive sleep apnea as a new indication for tirzepatide (Zepbound) and chronic obstructive pulmonary disease as a new indication for dupilumab (Dupixent)."

Journal • Addiction (Opioid and Alcohol) • Allergy • Alzheimer's Disease • Chronic Obstructive Pulmonary Disease • CNS Disorders • Endocrine Disorders • Hypoparathyroidism • Immunology • Obstructive Sleep Apnea • Psychiatry • Pulmonary Disease • Respiratory Diseases • Schizophrenia • Sleep Disorder

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction (ESC-WCC 2025) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice (ESC-WCC 2025) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction (ESC-WCC 2025) - No abstract available

Late-breaking abstract • Cardiovascular

Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. (PubMed, Obesity (Silver Spring)) - P3 | "In this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups."

Journal • Retrospective data • Genetic Disorders • Obesity

OPTIMAL: Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (clinicaltrials.gov) - P4 | N=70 | Recruiting | Sponsor: The Cleveland Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Fibrosis • Genetic Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Obesity • Portal Hypertension

Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity. (PubMed, Pharmacoeconomics) - "The cost effectiveness of pharmacotherapies for obesity (such as semaglutide, tirzepatide, liraglutide, and newer agents) is increasingly being appraised by health technology assessment (HTA) bodies. We speculate how these challenges relating to short-term clinical trials could be overcome to more robustly predict long-term outcomes and the role that observational data may play. As clinical trial and real-world evidence for technologies for obesity evolves, analysts and decision-makers need to determine which evidence sources are most appropriate and how they should be combined."

HEOR • Journal • Review • Genetic Disorders • Obesity